Exact Mass: 678.3284954000001
Exact Mass Matches: 678.3284954000001
Found 140 metabolites which its exact mass value is equals to given mass value 678.3284954000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Medicagenic acid 3-O-b-D-glucuronide
Medicagenic acid 3-O-b-D-glucuronide is found in cereals and cereal products. Medicagenic acid 3-O-b-D-glucuronide is a constituent of the roots of Medicago sativa (alfalfa) Constituent of the roots of Medicago sativa (alfalfa). Medicagenic acid 3-O-b-D-glucuronide is found in cereals and cereal products.
1-Acetyl-3,14,20-trihydroxywitha-5,24-dienolide 3-glucoside
1-Acetyl-3,14,20-trihydroxywitha-5,24-dienolide 3-glucoside is found in fruits. 1-Acetyl-3,14,20-trihydroxywitha-5,24-dienolide 3-glucoside is a constituent of Physalis peruviana (Cape gooseberry).
Hv-NCC-1
So-NCC-2 is found in brassicas. So-NCC-2 is isolated from spinach. Isolated from spinach. So-NCC-2 is found in brassicas.
Galnon
PA(10:0/6 keto-PGF1alpha)
PA(10:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/6 keto-PGF1alpha), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(6 keto-PGF1alpha/10:0)
PA(6 keto-PGF1alpha/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/10:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(10:0/TXB2)
PA(10:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(10:0/TXB2), in particular, consists of one chain of one decanoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(TXB2/10:0)
PA(TXB2/10:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/10:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of decanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Bryoamaride
Origin: Plant; SubCategory_DNP: Triterpenoids
1-(2-methylpropanoyl)-3-acetyl-11-methoxymeliacarpinin
6-O-Acetyl-2,3,4-tri-O-(3S-methylpentanoyl)-alpha-D-glucopyranosyl-beta-D-fructofuranoside|6-O-acetyl-2,3,4-tri-O-<(S)-3-methylpentanoyl>sucrose|6-O-acetyl-2,3,4-tri-O-<3S-methylpentanoyl>-sucrose
24-O-(3-O-Methyl-4-O-Sulfo-beta-D-xylofuranoside)-Cholestane-3,6,8,15,24-pentol
19-hydroxy-3-epi-ervafolidine|19S-Hydroxy-3-epiervafoline
4-acetoxy-1beta-(2-methylbutyryloxy)-8,10-epoxyabrotanifolone
3beta-(O4-glucopyranosyl-O3-methyl-beta-D-xylo-2,6-dideoxy-hexopyranosyloxy)-14-hydroxy-5beta-14beta-carda-16,20(22)-dienolide|3beta-(O4-Glucopyranosyl-O3-methyl-beta-D-xylo-2,6-didesoxy-hexopyranosyloxy)-14-hydroxy-5beta-14beta-carda-16,20(22)-dienolid
1alpha,6beta-diacetoxy-2alpha,9beta-dibenzoyloxy-15-isobutanoyloxy-beta-dihydroagarofuran|fokienagarofuran C
2,3-di-O-(5-methylheptanoyl)-1,6-di-O-acetylsucrose
3beta-(O4-beta-D-Digitoxopyranosyl-beta-D-digitoxopyranosyloxy)-16beta-formyloxy-14-hydroxy-5beta,14beta-card-20(22)-enolid|3beta-(O4-beta-D-digitoxopyranosyl-beta-D-digitoxopyranosyloxy)-16beta-formyloxy-14-hydroxy-5beta,14beta-card-20(22)-enolide
2-O-acetyl-3-O-decanoyl-3,4-di-O-isobutyrylsucrose
2alpha,7alpha-diacetoxy-1alpha,11alpha-dibenzoyloxy-3alpha,8beta-dihydroxyisopimar-14-one|orthoarisin E
3alpha,7alpha-diacetoxy-1alpha,11alpha-dibenzoyloxy-2alpha,8beta-dihydroxyisopimar-14-one|orthoarisin F
premyrsinol-3-propanoate-5-(alpha-methyl)butyrate-7,13-diacetate-17-isobutyrate
2,4,1-tri-O-(3-methylbutyryl)-3-O-(2-methylbutyryl)-sucrose
C36H54O12_Estr-5-ene-3,11-dione, 17-[(1R,3E)-1,5-dihydroxy-1,5-dimethyl-2-oxo-3-hexen-1-yl]-2-(beta-D-glucopyranosyloxy)-16-hydroxy-4,4,9,14-tetramethyl-, (2beta,9beta,10alpha,16alpha,17beta)
C36H54O12_2,7-Octadienoic acid, 6-[[3,4-bis-O-[(2E)-6-hydroxy-2,6-dimethyl-1-oxo-2,7-octadien-1-yl]-beta-D-glucopyranosyl]oxy]-2,6-dimethyl-, (2E)
C32H54O15_1,3,4,6-Tetrakis-O-(3-methylbutanoyl)-beta-D-fructofuranosyl alpha-D-glucopyranoside
C32H54O15_1,3,6-Tris-O-(3-methylbutanoyl)-beta-D-fructofuranosyl 2-O-(3-methylbutanoyl)-alpha-D-glucopyranoside
C34H46O14_Propanoic acid, 2-methyl-, (2R,3R,3aS,4R,6S,7R,10E,12R,13aR)-2,3,4,6,13a-pentakis(acetyloxy)-2,3,3a,4,5,6,7,8,9,12,13,13a-dodecahydro-2,9,9,12-tetramethyl-5-methylene-8,13-dioxo-1H-cyclopentacyclododecen-7-yl ester
1-Acetyl-3,14,20-trihydroxywitha-5,24-dienolide 3-glucoside
Medicagenic acid 3-O-b-D-glucuronide
Hv-NCC-1
6-O-succinyl methyl ester macrolactin O
OKODiA-PG
C32H55O13P (678.3380109999999)
2-(2-Ethoxyphenyl)-4,5-diphenylimidazole-1,2-dimer
9H-Fluoren-2-aMine, N-[1,1-biphenyl]-4-yl-9,9-diMethyl-N-[4-(9-phenyl-9H-carbazol-3-yl)phenyl]-
R-(R*,S*)]-[[2-methyl-1-(1-oxopropoxy)propoxy]-(4-phenylbutyl)phosphinyl] acetic acid, (-)-cinchonidine (1:1) salt
C38H51N2O7P (678.3433706000001)
N2,N7-DIPHENYL-N2,N7-DI-M-TOLYL-9,9-SPIROBI[FLUORENE]-2,7-DIAMINE
meso-Tetrakis(2-N-methylpyridyl)porphine
D011838 - Radiation-Sensitizing Agents > D017319 - Photosensitizing Agents D006133 - Growth Substances > D043924 - Angiogenesis Modulating Agents D000970 - Antineoplastic Agents > D020533 - Angiogenesis Inhibitors D006133 - Growth Substances > D006131 - Growth Inhibitors D000890 - Anti-Infective Agents D003879 - Dermatologic Agents D004791 - Enzyme Inhibitors
Maropitant citrate
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents
[6-[4-Acetyloxy-3-hydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-di(hexanoyloxy)-2-(hydroxymethyl)oxan-3-yl] hexanoate
Sucrose-2-(2-methyl)butyryl-4-(2-methyl)butyryl-3-(4-methyl)pentanoyl-6-isobutyrate
4-(dimethylamino)-N-[[(3R,9R,10S)-16-[(4-fluorophenyl)sulfonylamino]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-9-yl]methyl]-N-methylbutanamide
C34H51FN4O7S (678.3462308000001)
(1R,2R,3aR,5R,6E,10R,11S,13R,13aS)-1,3,3a,5,8,10,11,12,13,13a-Decahydro-1,2,3a,11,13-pentaacetoxy-10-(isobutyryloxy)-2,5,8,8-tetramethyl-12-methylene-4H-cyclopentacyclododecene-4,9(2H)-dione
[1-heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C32H55O13P (678.3380109999999)
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
C32H55O13P (678.3380109999999)
[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
C32H55O13P (678.3380109999999)